Literature DB >> 12525442

Effect of long-term treatment with low-dose mifepristone on the endometrium.

D T Baird1, A Brown, H O D Critchley, A R Williams, S Lin, L Cheng.   

Abstract

BACKGROUND: Mifepristone in low daily doses has contraceptive potential by inhibiting ovulation and menstruation. Because follicular development is maintained, the endometrium is exposed to estrogen for prolonged periods unopposed by progesterone.
METHODS: Endometrial biopsies were collected from 90 women in Edinburgh and Shanghai before (late proliferative) and 60 and 120 days after taking 2 or 5 mg mifepristone per day for 120 days.
RESULTS: Ovulation and menstruation were inhibited in >90% of cycles and estrogen production was similar to that observed during the follicular phase of the control cycle. By 120 days, endometrial thickness increased significantly in women in Edinburgh but decreased in Shanghai. Endometrial histology showed inactive proliferative or cystic changes with dense stroma. There was a significant decrease in markers of proliferation, i.e. mitotic index and Ki67 staining. There were no pregnancies in a total of 200 women-months in 50 sexually active women who used no other method of contraception.
CONCLUSIONS: We confirm that ovulation and menstruation were suppressed in the majority of cycles and there was asynchrony between ovarian activity and endometrial histology, which showed no signs of hyperplasia or atypia. These preliminary data suggest that daily low-dose mifepristone is potentially a safe estrogen-free contraceptive pill which has the added health benefit of amenorrhoea.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525442     DOI: 10.1093/humrep/deg022

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  9 in total

Review 1.  The role of progesterone signaling in the pathogenesis of uterine leiomyoma.

Authors:  J Julie Kim; Elizabeth C Sefton
Journal:  Mol Cell Endocrinol       Date:  2011-06-06       Impact factor: 4.102

2.  Mifepristone-exposured human endometrial endothelial cells in vitro.

Authors:  Malin Helmestam; Karin Elvine Lindgren; Anneli Stavreus-Evers; Matts Olovsson
Journal:  Reprod Sci       Date:  2013-07-24       Impact factor: 3.060

3.  Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques.

Authors:  Robert M Brenner; Ov D Slayden; Anita Nath; Y Y Tsong; Regine Sitruk-Ware
Journal:  Contraception       Date:  2009-12-16       Impact factor: 3.375

4.  A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception.

Authors:  YongMei Huang; Jeffrey T Jensen; Vivian Brache; Leila Cochon; Alistair Williams; Maria-José Miranda; Horacio Croxatto; Narender Kumar; Heather Sussman; Elena Hoskin; Marlena Plagianos; Kevin Roberts; Ruth Merkatz; Diana Blithe; Regine Sitruk-Ware
Journal:  Contraception       Date:  2014-08-12       Impact factor: 3.375

5.  Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial.

Authors:  Josep Ll Carbonell; Rita Acosta; Yasmiriam Pérez; Ana G Marrero; Edilia Trellez; Carlos Sánchez; Giuseppe Tomasi
Journal:  Int J Womens Health       Date:  2013-03-19

6.  Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery.

Authors:  Josep L Carbonell Esteve; Ana M Riverón; Mariela Cano; Alma I Ortiz; Aleta Valle; Carlos S Texidó; Giuseppe Tomasi
Journal:  Int J Womens Health       Date:  2012-03-13

7.  Current and emerging treatments for uterine myoma - an update.

Authors:  Nirmala Duhan
Journal:  Int J Womens Health       Date:  2011-08-08

8.  Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India.

Authors:  Vidushi Kulshrestha; Alka Kriplani; Nutan Agarwal; Neetu Sareen; Pradeep Garg; Smriti Hari; Jyoti Thulkar
Journal:  Indian J Med Res       Date:  2013-06       Impact factor: 2.375

Review 9.  Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies.

Authors:  Andrea Wagenfeld; Philippa T K Saunders; Lucy Whitaker; Hilary O D Critchley
Journal:  Expert Opin Ther Targets       Date:  2016-05-14       Impact factor: 6.902

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.